Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice

Bersudsky, Marina; Luski, L.; Fishman, Daniel; White, Rosalyn M.; Ziv-Sokolovskaya, Nadya; Dotan, Shahar; Rider, Peleg; Kaplanov, Irena; Aychek, Tegest; Dinarello, Charles A.; Apte, Ron N.; Voronov, Elena

doi:10.1136/gutjnl-2012-303329

Cited by 219 publications

(202 citation statements)

References 50 publications

Supporting

Mentioning

189

Contrasting

Unclassified

Order By: Relevance

“…190 Arginase produced by alternatively activated m in parasite infections is a further important tissue repair mechanism under these conditions. 194,195 Although generally thought of as a pro-inflammatory mediator, IL-1 production by myeloid cells has also been shown to promote epithelial repair after acute colitis, 196 while IL-36 produced by both m and epithelial cells may contribute to enhanced turnover of enterocytes as a reparative response to inflammation. 197 As many of the properties of resident m in the healthy intestine would be ideally suited to help in tissue repair, cells of this kind that have survived the initial inflammatory insult may be important in this process.…”

Section: Macrophages In Intestinal Inflammationmentioning

confidence: 99%

Diversity and functions of intestinal mononuclear phagocytes

et al. 2017

View full text Add to dashboard Cite

Section: Macrophages In Intestinal Inflammationmentioning

confidence: 99%

Diversity and functions of intestinal mononuclear phagocytes

et al. 2017

View full text Add to dashboard Cite

“…Although anakinra will prevent the activity of IL-1α and IL-1β, there is a need to selectively block IL-1α but not IL-1β. The rationale for this concept is based on a model of inflammatory bowel disease in mice in which IL-1α mediates the inflammation, whereas IL-1β mediates healing (125). …”

Section: The Case For Treating Cancer With Anti-il-1αmentioning

confidence: 99%

An Expanding Role for Interleukin-1 Blockade from Gout to Cancer

Dinarello

2014

Mol Med

View full text Add to dashboard Cite

There is an expanding role for interleukin (IL)-1 in diseases from gout to cancer. More than any other cytokine family, the IL-1 family is closely linked to innate inflammatory and immune responses. This linkage is because the cytoplasmic segment of all members of the IL-1 family of receptors contains a domain, which is highly homologous to the cytoplasmic domains of all toll-like receptors (TLRs). This domain, termed "toll IL-1 receptor (TIR) domain," signals as does the IL-1 receptors; therefore, inflammation due to the TLR and the IL-1 families is nearly the same. Fundamental responses such as the induction of cyclo-oxygenase type 2, increased surface expression of cellular adhesion molecules and increased gene expression of a broad number of inflammatory molecules characterizes IL-1 signal transduction as it does for TLR agonists. IL-1β is the most studied member of the IL-1 family because of its role in mediating autoinflammatory disease. However, a role for IL-1α in disease is being validated because of the availability of a neutralizing monoclonal antibody to human IL-1α. There are presently three approved therapies for blocking IL-1 activity. Anakinra is a recombinant form of the naturally occurring IL-1 receptor antagonist, which binds to the IL-1 receptor and prevents the binding of IL-1β as well as IL-1α. Rilonacept is a soluble decoy receptor that neutralizes primarily IL-1β but also IL-1α. Canakinumab is a human monoclonal antibody that neutralizes only IL-1β. Thus, a causal or significant contributing role can be established for IL-1β and IL-1α in human disease.

show abstract

“…MAAs had been shown to regulate intestinal epithelial cell differentiation and cytokine (IL-1β, IL-6) production [21]. Increased cytokine production, NF-κB activation induced a proliferative effect on epithelial intestinal cells and protect them in experimental colitis secondary to dextran sulphate sodium [22][23][24][25][26]. In vivo experiments showed antiinflammatory effect of MAAs, indicating that they can reinforce membrane barrier function [27][28].…”

Section: Mycosporin-like Amino Acidsmentioning

confidence: 99%

Can Fortified Bifidobacterium with Mycosporin-like Amino Acid be a New Insight for Neurological Disease' s Treatment?

Bozkurt¹,

Kara²

2018

Autism Open Access

View full text Add to dashboard Cite

Gastrointestinal microbiota includes bacteria, archaea, viruses, fungi and other eukaryotes. The genus Bifidobacterium is considered the dominant once; it has an important role on immunologic, hormonal and metabolic homeostasis of the host. Recent studies demonstrated that the Mycosporin-like Amino Acids (MAAs) had prebiotic effects and they modulated host immunity by regulating the proliferation and differentiation of intestinal epithelial cells, macrophage and lymphocytes. Also MAAs modulate NF-κB and tryptophan metabolism. Modulation NF-κB and tryptophan metabolism induced a beneficial effect on central nervous cascade. The safety of Bifidobacterium species is known; although they do not produce MAAs, their presence is required for immunological response continuity of intestine. Thereby we hypothesize that if we could create Bifidobacteria species producing MAAs via genetic engineering; they might have stronger immuno-stimulatory properties and might be used as more potent pharmacological agents in neurological diseases secondary to impaired microbiota.

show abstract

Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice

Cited by 219 publications

References 50 publications

Diversity and functions of intestinal mononuclear phagocytes

Diversity and functions of intestinal mononuclear phagocytes

An Expanding Role for Interleukin-1 Blockade from Gout to Cancer

Can Fortified Bifidobacterium with Mycosporin-like Amino Acid be a New Insight for Neurological Disease' s Treatment?

Contact Info

Product

Resources

About